pre-IPO PHARMA

COMPANY OVERVIEW

Neurogastrx is a private biopharmaceutical company focused on discovering and developing transformative therapies for gastrointestinal disorders affecting the enteric nervous system.


LOCATION

  • Woburn, MA, USA

  • THERAPEUTIC AREAS

  • Gastrointestinal Disease

  • WEBSITE

    https://neurogastrx.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    5am-ventures orbimed venbio


    PRESS RELEASES


    Aug 26, 2021

    Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders


    Jun 8, 2021

    Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S.


    Jan 4, 2018

    Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept


    Nov 3, 2015

    Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer


    For More Press Releases


    Google Analytics Alternative